Eric D. Donnenfeld, MD is selected to be the first cataract surgeon in the country to launch EyePoint Pharmaceutical’s FDA-approved DEXYCU (dexamethasone intraocular suspension) 9% to improve post-operative cataract surgery patient compliance.

Back to News

Eric D. Donnenfeld, MD  of OCLI, Ophthalmic Consultants of Connecticut (“OCC”), Spectrum Vision Partners (“SVP”) managed practices, often sought for his expertise and innovation in the field of Ophthalmology, has successfully performed the first Cataract Surgery in the United States, utilizing FDA approved DEXYCU™ (dexamethasone intraocular suspension) 9%, at Island Eye Surgicenter in Westbury, NY.  EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, announced yesterday that it has commercially launched DEXYCU™ (dexamethasone intraocular suspension) 9% in the United States. DEXYCU is the first and only U.S. Food and Drug Administration (FDA) approved intraocular steroid for the treatment of postoperative inflammation and is administered as a single dose at the end of cataract surgery. DEXYCU is intended to replace the use of steroid eye drops which have a dosing regimen that, depending on the brand, can require self-administration for up to four times a day and titrating down over four weeks. This complicated dosing regimen can often lead to poor patient compliance.

Dr. Donnenfeld expresses his support of innovation to enhance patient outcome, “Today was an important day for Ophthalmology. The FDA approval of DEXYCU allows patients having cataract surgery to have their medication placed inside their eye. This improves patient compliance, quality of life and is the first step in eliminating eye drops in cataract surgery.”

The launch of DEXYCU will be phased, with the initial phase being to leading cataract surgery experts such as Dr. Donnenfeld, to ensure proper training on DEXYCU’s administration ahead of its wider availability in the ophthalmology community. EyePoint Assist, the Company-sponsored program designed to ensure access to DEXYCU, is available for eligible patients in need of financial assistance.

Tom Burke, CEO of Spectrum Vision Partners commented on today’s news, “Spectrum Vision Partners is proud to continue its collaboration with national leaders who bring the latest innovations in advanced cataract surgery to their patients. Dr. Donnenfeld, the OCLI vision experts and the Island Eye Surgicenter team have delivered another advancement to improve visual outcomes and their patients’ lives.  Performing the first FDA approved DEXYCU drug delivery in the United States is another example of their leadership in the ophthalmic field.   We applaud the success of Eye Point Pharmaceuticals with this application of their delivery system and look forward to continuing SVP’s collaboration with our doctors as they continue to improve patient care.”

“EyePoint is proud to announce the U.S. commercial launch of our second innovative ophthalmic product, DEXYCU, which is now available to cataract surgery patients to treat inflammation that occurs after this common surgical procedure. There are approximately 4.8 million cataract surgeries a year in the US,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals. “DEXYCU offers a single-dose, sustained release treatment option conveniently administered at the end of cataract surgery which can eliminate the complicated and burdensome steroid eyedrop regimen following surgery.”

DEXYCU is the first long-acting intraocular steroid approved by the FDA for the treatment of postoperative inflammation. Cataract surgery is the most frequent surgical procedure in the U.S., with approximately 4.8 million performed annually. DEXYCU employs the Company’s Verisome sustained-release drug delivery technology to deliver a biodegradable extended-release formulation of the steroid dexamethasone into the posterior chamber of the eye via a single injection at the end of surgery, eliminating the burden of self-administering steroid eye drops up to four times a day for several weeks on a titrated schedule, in a primarily elderly patient population.


Learn more about Eric Donnenfeld, MD

Learn more about Spectrum Vision Partners

Learn more about OCLI

Learn more about OCC

Learn more about Island Eye Surgicenter

Learn more about DEXYCU™

Learn more about EyePoint Pharmaceuticals

Safe Harbor Statements Under the Private Securities Litigation Act of 1995 

Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our commercialization of YUTIQ and DEXYCU, the expected timing of release of the 24-month and 36-month patient follow-up data for YUTIQ and our expectations regarding the timing of a filing of an application for approval of a next-generation, shorter-duration treatment for posterior segment uveitis, are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements include uncertainties with respect to: our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce commercial supply of YUTIQ and DEXYCU and commercialize YUTIQ and DEXYCU in the U.S.; our ability to successfully build a commercial infrastructure and enter into and maintain commercial agreements for the launch of DEXYCU and YUTIQ; the successful release of our YUTIQ line extension shorter-acting treatment for uveitis; potential off-label sales of ILUVIEN for non-infectious posterior segment uveitis (“NIPU”); consequences of fluocinolone acetonide side effects; successful commercialization of, and receipt of revenues from, ILUVIEN for diabetic macular edema (“DME”) which depends on the ability of Alimera Sciences, Inc. (“Alimera”) to continue as a going concern; Alimera’s ability to obtain additional marketing approvals and the effect of pricing and reimbursement decisions on sales of ILUVIEN for DME; Alimera’s ability to obtain marketing approval for ILUVIEN in its licensed territories for NIPU; potential declines in Retisert royalties; our ability to market and sell products; the success of current and future license agreements, including our agreement with Alimera; termination or breach of current license agreements, including our agreement with Alimera; our dependence on contract research organizations, contract sales organizations, vendors and investigators; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; effects of the potential exit of the United Kingdom from the European Union; legislative or regulatory changes; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. You should read and interpret any forward-looking statements in light of these risks. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

25 Responses to Eric D. Donnenfeld, MD is selected to be the first cataract surgeon in the country to launch EyePoint Pharmaceutical’s FDA-approved DEXYCU (dexamethasone intraocular suspension) 9% to improve post-operative cataract surgery patient compliance.

  • Brodie says:

    You’re so awesome! I don’t think I’ve read something
    like this before. So good to find somebody with genuine thoughts
    on this subject. Really.. many thanks for starting this up.
    This web site is one thing that is required on the web hosting reviews, someone with a
    little originality!

  • Deloras says:

    Hey there! I could have sworn I’ve been to this blog before but after browsing through
    some of the post I realized it’s new to me. Anyways, I’m definitely delighted I found
    it and I’ll be bookmarking and checking back frequently!
    adreamoftrains best hosting webhosting

  • Heriberto says:

    A motivating discussion is definitely worth comment.
    I do believe that you should publish more about this issue, it might not be a taboo matter but typically
    people don’t talk about such subjects. To the next!
    best web hosting 2020 wishes!!

  • Chanda says:

    It’s hard to find knowledgeable people in this particular subject, but you sound like you know what you’re talking about!


    my web blog: cheap flights

  • Corazon says:

    You could definitely see your expertise within the
    article you write. The sector hopes for more passionate writers like
    you who are not afraid to say how they believe. All the time follow your
    heart. cheap flights 32hvAj4

  • Clint says:

    I just could not leave your website prior to suggesting that I
    really loved the usual info a person supply for your visitors?

    Is going to be again ceaselessly to check up on new posts 31muvXS cheap flights

  • Daniella says:

    Hmm it seems like your website ate my first comment (it
    was extremely long) so I guess I’ll just sum it up what I submitted and say, I’m thoroughly
    enjoying your blog. I as well am an aspiring blog blogger but I’m still new to
    the whole thing. Do you have any helpful hints for beginner blog writers?
    I’d genuinely appreciate it.

    Have a look at my blog post … web hosting reviews

  • Margarito says:

    Hey just wanted to give you a brief heads up and let you know a few of the images aren’t loading correctly.
    I’m not sure why but I think its a linking issue. I’ve tried it
    in two different browsers and both show the same results.
    yynxznuh cheap flights

  • Hector says:

    Hi, i think that i saw you visited my web site so i came to
    “return the favor”.I am trying to find things to enhance my
    website!I suppose its ok to use some of your ideas!!
    cheap flights 31muvXS

  • Monte says:

    Hi! Would you mind if I share your blog with my twitter group?
    There’s a lot of people that I think would really appreciate your content.
    Please let me know. Many thanks cheap flights 32hvAj4

  • Earnestine says:

    excellent post, very informative. I’m wondering why the other specialists of
    this sector don’t understand this. You must proceed your writing.
    I am confident, you have a huge readers’ base already!

    my website; cheap flights

  • Maricruz says:

    Everything is very open with a precise clarification of the issues.
    It was truly informative. Your website is extremely helpful.
    Thanks for sharing!

    Here is my site: cheap flights

  • Muhammad says:

    We stumbled over here different page and thought I should check things out.
    I like what I see so i am just following you. Look forward
    to looking at your web page repeatedly.

    Here is my web site; cheap flights

  • Milford says:

    I’ve read several just right stuff here. Certainly value
    bookmarking for revisiting. I wonder how so much effort you set to create
    such a excellent informative site.

    My webpage :: cheap flights

  • Lorenza says:

    Today, I went to the beach with my kids. I found a sea shell and gave it to my 4 year old daughter and said “You can hear the ocean if you put this to your ear.” She placed
    the shell to her ear and screamed. There was a hermit crab inside and it pinched her ear.
    She never wants to go back! LoL I know this is entirely off topic but I had to tell someone!

    my homepage – cheap flights

  • Benito says:

    It’s awesome to visit this website and reading the views of all friends on the
    topic of this piece of writing, while I am also zealous of getting

    Also visit my website: cheap flights

  • Katie says:

    Wow, superb blog format! How lengthy have you been running a blog for?
    you made running a blog glance easy. The total glance
    of your site is great, as neatly as the content!

    Also visit my website … black mass

  • Mona says:

    If you want to increase your know-how simply keep visiting this website and be updated with the latest news posted here.

    Here is my website :: black mass

  • Katherina says:

    This is very interesting, You are a very skilled blogger.

    I have joined your feed and look forward to seeking more of
    your excellent post. Also, I’ve shared your web site in my social networks!

    my web site; black mass

  • Brooks says:

    An impressive share! I’ve just forwarded this onto
    a coworker who had been doing a little research on this.
    And he actually ordered me breakfast due to the fact that I found it for him…
    lol. So let me reword this…. Thanks for the meal!!

    But yeah, thanks for spending time to discuss this subject here on your best web hosting company page.

  • Nelly says:

    I’ve been exploring for a little for any high quality articles
    or blog posts in this kind of space . Exploring in Yahoo I at last stumbled upon this website.
    Reading this info So i am glad to exhibit that I have a very just right uncanny feeling I discovered
    just what I needed. I such a lot definitely will make certain to
    don?t omit this web hosting company
    site and provides it a glance on a constant basis.

Leave a Reply

Fields marked with * are required.